Journal of Clinical Oncology, Vol 16, 536-544, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Second cancers following pediatric Hodgkin's disease

SL Wolden, KR Lamborn, SF Cleary, DJ Tate and SS Donaldson
Department of Radiation Oncology, Stanford University Medical Center, CA 94305, USA.

PURPOSE: To define the magnitude of second cancer risk among pediatric Hodgkin's disease survivors and to determine which factors influence this risk. PATIENTS AND METHODS: At Stanford,694 children and teenagers were monitored for 1 to 31.6 years (mean, 13.1) after treatment for Hodgkin's disease. Relative risks (RRs), actuarial risks, and absolute excess risks for second malignancies were calculated. The influences of sex, age, stage, splenectomy, treatment and relapse were assessed by multivariate analysis. RESULTS: Fifty-six patients developed 59 secondary malignancies: 48 solid tumors, eight leukemias, and three non- Hodgkin's lymphomas. The RR of developing a second cancer was 15.4 (95% confidence interval [CI], 10.6 to 21.5) for females and 10.6 (95% CI, 6.6 to 16.0) for males. Breast cancer (n = 16) and sarcoma (n = 13) were the most common solid tumors. The actuarial risk at 20 years follow-up evaluation was 9.7% for males, 16.8% for females, and 9.2% for breast cancer. The median interval to diagnosis of a second malignancy was shortest for leukemia, 4.3 years, and longest for lung cancer, 18.4 years. Relapse of Hodgkin's disease increased the risk of second malignancy (hazards ratio [HR] = 2.6, P < .001). Hodgkin's disease stage, patient age, splenectomy, and treatment modality did not appear to alter overall risk, although chemotherapy was associated with subsequent leukemia. CONCLUSION: Aggressive Hodgkin's disease therapy is successful, but patients have a significant risk of second malignancy. Newer treatment programs focus on obtaining a relapse-free cure of Hodgkin's disease with judicious use of radiation and alkylating agent chemotherapy. Survivors of pediatric Hodgkin's disease require lifelong evaluation and cancer screening.

This article has been cited by other articles:

				D. L. Friedman, A. Rovo, W. Leisenring, A. Locasciulli, M. E. D. Flowers, A. Tichelli, J. E. Sanders, H. J. Deeg, and G. Socie Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party Blood, January 15, 2008; 111(2): 939 - 944. [Abstract] [Full Text] [PDF]

				G. T. Armstrong, C. A. Sklar, M. M. Hudson, and L. L. Robison Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter? J. Clin. Oncol., October 1, 2007; 25(28): 4477 - 4489. [Abstract] [Full Text] [PDF]

				S. Guerin, M. Hawkins, A. Shamsaldin, C. Guibout, I. Diallo, O. Oberlin, L. Brugieres, and F. de Vathaire Treatment-Adjusted Predisposition to Second Malignant Neoplasms After a Solid Cancer in Childhood: A Case-Control Study J. Clin. Oncol., July 1, 2007; 25(19): 2833 - 2839. [Abstract] [Full Text] [PDF]

				F. Castiglioni, M. Terenziani, M. L. Carcangiu, R. Miliano, P. Aiello, L. Bertola, T. Triulzi, P. Gasparini, T. Camerini, G. Sozzi, et al. Radiation Effects on Development of HER2-Positive Breast Carcinomas Clin. Cancer Res., January 1, 2007; 13(1): 46 - 51. [Abstract] [Full Text] [PDF]

				P H Jarritt, K J Carson, A R Hounsell, and D Visvikis The role of PET/CT scanning in radiotherapy planning Br. J. Radiol., September 1, 2006; 79(Special_Issue_1): S27 - S35. [Abstract] [Full Text] [PDF]

				M. Bassal, A. C. Mertens, L. Taylor, J. P. Neglia, B. S. Greffe, S. Hammond, C. M. Ronckers, D. L. Friedman, M. Stovall, Y. Y. Yasui, et al. Risk of Selected Subsequent Carcinomas in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study J. Clin. Oncol., January 20, 2006; 24(3): 476 - 483. [Abstract] [Full Text] [PDF]

				J. L. Perkins, Y. Liu, P. A. Mitby, J. P. Neglia, S. Hammond, M. Stovall, A. T. Meadows, R. Hutchinson, Z. E. Dreyer, L. L. Robison, et al. Nonmelanoma Skin Cancer in Survivors of Childhood and Adolescent Cancer: A Report From the Childhood Cancer Survivor Study J. Clin. Oncol., June 1, 2005; 23(16): 3733 - 3741. [Abstract] [Full Text] [PDF]

				Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540. [Abstract] [Full Text] [PDF]

				K. E. Nichols, J. A. Heath, D. Friedman, J. A. Biegel, A. Ganguly, P. Mauch, and L. Diller TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin's Disease With Second Primary Neoplasms J. Clin. Oncol., December 15, 2003; 21(24): 4505 - 4509. [Abstract] [Full Text] [PDF]

				S. Bhatia, Y. Yasui, L. L. Robison, J. M. Birch, M. K. Bogue, L. Diller, C. DeLaat, F. Fossati-Bellani, E. Morgan, O. Oberlin, et al. High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin's Disease: Report From the Late Effects Study Group J. Clin. Oncol., December 1, 2003; 21(23): 4386 - 4394. [Abstract] [Full Text] [PDF]

				C. L. Schwartz Health Status of Childhood Cancer Survivors: Cure Is More Than the Eradication of Cancer JAMA, September 24, 2003; 290(12): 1641 - 1643. [Full Text] [PDF]

				J. Yahalom Breast Cancer After Hodgkin Disease: Hope for a Safer Cure JAMA, July 23, 2003; 290(4): 529 - 531. [Full Text] [PDF]

				F. E. van Leeuwen, W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. P. Aleman, A. Broeks, M. Gospodarowicz, et al. Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease J Natl Cancer Inst, July 2, 2003; 95(13): 971 - 980. [Abstract] [Full Text] [PDF]

				M. M. Hudson Pediatric Hodgkin's Therapy: Time for a Paradigm Shift J. Clin. Oncol., September 15, 2002; 20(18): 3755 - 3757. [Full Text] [PDF]

				J. B. Nachman, R. Sposto, P. Herzog, G. S. Gilchrist, S. L. Wolden, J. Thomson, M. E. Kadin, P. Pattengale, P. C. Davis, R. J. Hutchinson, et al. Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin's Disease Who Achieve a Complete Response to Chemotherapy J. Clin. Oncol., September 15, 2002; 20(18): 3765 - 3771. [Abstract] [Full Text] [PDF]

				G. M. Dores, C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, F. E. van Leeuwen, E. J. Holowaty, et al. Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years J. Clin. Oncol., August 15, 2002; 20(16): 3484 - 3494. [Abstract] [Full Text] [PDF]

				A. M. Friedmann, M. M. Hudson, H. J. Weinstein, S. S. Donaldson, L. Kun, N. J. Tarbell, and M. P. Link Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation J. Clin. Oncol., July 15, 2002; 20(14): 3088 - 3094. [Abstract] [Full Text] [PDF]

				J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression Cancer Res., December 1, 2001; 61(23): 8513 - 8519. [Abstract] [Full Text] [PDF]

				J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 5, 2001; (2001) 191211198. [Abstract] [Full Text] [PDF]

				M. G. Backlund, S. L. Trasti, D. C. Backlund, V. L. Cressman, V. Godfrey, and B. H. Koller Impact of Ionizing Radiation and Genetic Background on Mammary Tumorigenesis in p53-deficient Mice Cancer Res., September 1, 2001; 61(17): 6577 - 6582. [Abstract] [Full Text] [PDF]

				J. P. Neglia, D. L. Friedman, Y. Yasui, A. C. Mertens, S. Hammond, M. Stovall, S. S. Donaldson, A. T. Meadows, and L. L. Robison Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study J Natl Cancer Inst, April 18, 2001; 93(8): 618 - 629. [Abstract] [Full Text] [PDF]

				S. Waxman and K. C. Anderson History of the Development of Arsenic Derivatives in Cancer Therapy Oncologist, April 1, 2001; 6(90002): 3 - 10. [Abstract] [Full Text]

				E. C. Walter and D. S. Hawkins The Utility of Skin Biopsies in Pediatric Cancer Patients: A Single-Institution, Retrospective Review Clinical Pediatrics, March 1, 2001; 40(3): 139 - 147. [Abstract] [PDF]

				C. Sklar, J. Whitton, A. Mertens, M. Stovall, D. Green, N. Marina, B. Greffe, S. Wolden, and L. Robison Abnormalities of the Thyroid in Survivors of Hodgkin's Disease: Data from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3227 - 3232. [Abstract] [Full Text]

				A.-M. Martin and B. L. Weber Genetic and Hormonal Risk Factors in Breast Cancer J Natl Cancer Inst, July 19, 2000; 92(14): 1126 - 1135. [Abstract] [Full Text] [PDF]

				C. Metayer, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, T. Joensuu, F. E. van Leeuwen, M. B. van't Veer, R. E. Curtis, et al. Second Cancers Among Long-Term Survivors of Hodgkin's Disease Diagnosed in Childhood and Adolescence J. Clin. Oncol., June 12, 2000; 18(12): 2435 - 2443. [Abstract] [Full Text] [PDF]

				D. M. Green, A. Hyland, M. P. Barcos, J. A. Reynolds, R. J. Lee, B. C. Hall, and M. A. Zevon Second Malignant Neoplasms After Treatment for Hodgkin’s Disease in Childhood or Adolescence J. Clin. Oncol., April 7, 2000; 18(7): 1492 - 1499. [Abstract] [Full Text] [PDF]

				S. L. Wolden, S. L. Hancock, R. W. Carlson, D. R. Goffinet, S. S. Jeffrey, and R. T. Hoppe Management of Breast Cancer After Hodgkin’s Disease J. Clin. Oncol., February 14, 2000; 18(4): 765 - 765. [Abstract] [Full Text] [PDF]

				F. E. van Leeuwen, W. J. Klokman, M. B. v.’t Veer, A. Hagenbeek, A. D. G. Krol, U. A. O. Vetter, M. Schaapveld, P. van Heerde, J. M. V. Burgers, R. Somers, et al. Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood J. Clin. Oncol., February 1, 2000; 18(3): 487 - 487. [Abstract] [Full Text] [PDF]

				D. L. Cooper, A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Radiation for Early-Stage Hodgkin’s Disease? J. Clin. Oncol., February 1, 2000; 18(4): 943 - 943. [Full Text] [PDF]

				G. Socie, R. E. Curtis, H. J. Deeg, K. A. Sobocinski, A. H. Filipovich, L. B. Travis, K. M. Sullivan, P. A. Rowlings, D. W. Kingma, P. M. Banks, et al. New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia J. Clin. Oncol., January 14, 2000; 18(2): 348 - 348. [Abstract] [Full Text] [PDF]

				D. C. Linch, R. G. Gosden, T. Tulandi, S.-L. Tan, and S. L. Hancock Hodgkin's Lymphoma: Choice of Therapy and Late Complications Hematology, January 1, 2000; 2000(1): 205 - 221. [Abstract] [Full Text] [PDF]

				K. E. Nichols, S. Levitz, K. E. Shannon, D. C.R. Wahrer, D. W. Bell, G. Chang, S. Hegde, D. Neuberg, T. Shafman, N. J. Tarbell, et al. Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease J. Clin. Oncol., April 1, 1999; 17(4): 1259 - 1259. [Abstract] [Full Text] [PDF]

				A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]

				C. A. Felix, A. H. Walker, B. J. Lange, T. M. Williams, N. J. Winick, N.-K. V. Cheung, B. D. Lovett, P. C. Nowell, I. A. Blair, and T. R. Rebbeck Association of CYP3A4 genotype with treatment-related leukemia PNAS, October 27, 1998; 95(22): 13176 - 13181. [Abstract] [Full Text] [PDF]

				J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 25, 2001; 98(20): 11592 - 11597. [Abstract] [Full Text] [PDF]